resolvin E1 RvE1
Selected indexed studies
- Resolvin E1/ChemR23 Protects Against Hypertension and Vascular Remodeling in Angiotensin II-Induced Hypertensive Mice. (Hypertension, 2023) [PMID:37800344]
- Imbalanced serum levels of resolvin E1 (RvE1) and leukotriene B4 (LTB4) may contribute to the pathogenesis of atherosclerosis. (Prostaglandins Other Lipid Mediat, 2023) [PMID:37704124]
- Adiposity associates with lower plasma resolvin E1 (Rve1): a population study. (Int J Obes (Lond), 2024) [PMID:38347128]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Resolvin E1/ChemR23 Protects Against Hypertension and Vascular Remodeling in Angiotensin II-Induced Hypertensive Mice. (2023) pubmed
- Imbalanced serum levels of resolvin E1 (RvE1) and leukotriene B4 (LTB4) may contribute to the pathogenesis of atherosclerosis. (2023) pubmed
- Adiposity associates with lower plasma resolvin E1 (Rve1): a population study. (2024) pubmed
- The role of polyunsaturated ω-3 fatty acid eicosapentaenoic acid-derived resolvin E1 (RvE1) in bone preservation. (2014) pubmed
- Resolvin E1 improves efferocytosis and rescues severe aplastic anemia in mice. (2024) pubmed
- Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis. (2015) pubmed
- Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study. (2019) pubmed
- Imbalanced serum levels of resolvin E1 (RvE1) and leukotriene B4 (LTB4) in patients with allergic rhinitis. (2020) pubmed
- ChemR23 activation attenuates cognitive impairment in chronic cerebral hypoperfusion by inhibiting NLRP3 inflammasome-induced neuronal pyroptosis. (2023) pubmed
- Resolvin E1's Antimicrobial Potential Against Aggregatibacter Actinomycetemcomitans. (2022) pubmed